title: Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer.
abstract: BACKGROUND
  The purpose of this study was to evaluate the efficacy of superselective cisplatin infusion with concomitant radiotherapy (RADPLAT) for previously untreated patients with the squamous cell carcinoma of maxillary sinus (SCC-MS).
  
  
  METHODS
  Between 1999 and 2010, 54 patients were given superselective intra-arterial infusions of cisplatin (100-120 mg m(-2) per week) with simultaneous intra-venous infusions of thiosulfate to neutralise cisplatin toxicity and conventional radiotherapy (65-70 Gy).
  
  
  RESULTS
  One patient (1.9%) was diagnosed with T2, 14 (25.9%) with T3, 27 (50%) with T4a, and 12 (22.2%) with T4b disease. Lymph-node involvement was present in 12 patients (22.2%). During the median follow-up period of 6.4 years, the 5-year local progression-free and overall survival rates were 65.8 and 67.9% for all patients, respectively. No patient died as a result of treatment toxicity or experienced a cerebrovascular accident. Osteonecrosis (n=5), brain necrosis (n=1), and ocular/visual problems (n=14) were observed as late adverse reactions.
  
  
  CONCLUSIONS
  We have shown excellent overall survival and local progression-free rate in SCC-MS patients treated by RADPLAT with acceptable rates of acute and late toxicity. A multi-institutional trial is needed to prove that this strategy is a feasible and effective approach for the treatment of SCC-MS.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 7, Kita-ku, Sapporo 060-8638, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Homma
authors.forename: T
authors.initials: T
authors.lastname: Sakashita
authors.forename: D
authors.initials: D
authors.lastname: Yoshida
authors.forename: R
authors.initials: R
authors.lastname: Onimaru
authors.forename: K
authors.initials: K
authors.lastname: Tsuchiya
authors.forename: F
authors.initials: F
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Yasuda
authors.forename: H
authors.initials: H
authors.lastname: Hatakeyama
authors.forename: J
authors.initials: J
authors.lastname: Furusawa
authors.forename: T
authors.initials: T
authors.lastname: Mizumachi
authors.forename: S
authors.initials: S
authors.lastname: Kano
authors.forename: N
authors.initials: N
authors.lastname: Inamura
authors.forename: S
authors.initials: S
authors.lastname: Taki
authors.forename: H
authors.initials: H
authors.lastname: Shirato
authors.forename: S
authors.initials: S
authors.lastname: Fukuda
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008297:Male; D008444:Maxillary Sinus Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D008875:Middle Aged; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D000077195:Squamous Cell Carcinoma of Head and Neck; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D002945:Cisplatin